Biomarkers in Samples From Young Patients With Neuroblastoma

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: May 18, 2011
Last updated: September 30, 2015
Last verified: May 2015

RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.

Condition Intervention
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Genetic: western blotting
Other: flow cytometry
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: ROR1 as a Novel Target for Neuroblastoma

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: May 2011
Estimated Primary Completion Date: January 2100 (Final data collection date for primary outcome measure)
Detailed Description:



  • To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.
  • To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.

OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.


Ages Eligible for Study:   up to 120 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed with neuroblastoma.



  • Diagnosed with neuroblastoma

    • With or without N-myc amplification
  • Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C
  • Bone marrow samples from high-risk patients as peripheral blood mononuclear cells (PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow cytometry or slides of bone marrow that can be used for immunohistochemistry


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01358604

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: David Hema, MD, MPH NCI - Experimental Transplantation and Immunology Branch
  More Information

Additional Information:
No publications provided

Responsible Party: Children's Oncology Group Identifier: NCT01358604     History of Changes
Other Study ID Numbers: ANBL11B2, COG-ANBL11B2, NCI-2011-02855, ANBL11B2
Study First Received: May 18, 2011
Last Updated: September 30, 2015
Health Authority: United States: Federal Government

Keywords provided by Children's Oncology Group:
localized resectable neuroblastoma
recurrent neuroblastoma
regional neuroblastoma
stage 4S neuroblastoma
localized unresectable neuroblastoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral processed this record on October 02, 2015